Published
March 8, 2026
Updated
August 31, 2026
People who paid out of pocket or through insurance for generic prescription drugs between May 1, 2009 and December 31, 2019 may qualify to claim a share of the end-payer settlements, part of more than $850 million recovered in the generic drug price-fixing litigation. End-payer claims are open through November 9, 2026, and pharmacy records, receipts or insurer statements are required.
Can I File a Claim Now?
Yes — on the federal End-Payer program. This is a change from earlier in 2026, when every program was registration-only. Court-appointed class counsel has begun accepting claims for the combined End-Payer settlements (Sandoz, Sun/Taro, and Apotex/Heritage), and the deadline to file is November 9, 2026. If you are a consumer or a health plan that paid for covered generic drugs between May 2009 and December 2019, you can file now at the End-Payer site.The separate State Attorneys General consumer program (AGGenericDrugs.com) is still registration-only — no claim form has opened there yet — so if you think you also qualify under that program, register to be notified when its claims open. The two programs are independent, and filing on one does not file you on the other.
Status
End-Payer Claims Open
State-AG consumer program is still register-only.
End-Payer Claim Deadline
November 9, 2026
Sandoz, Sun/Taro, and Apotex/Heritage combined process.
Combined Total
Over $850 million
Across the end-payer, state-AG, and direct-purchaser programs.
Proof Required
Yes
Proof of purchase — pharmacy records, receipts, or insurer statements.
Purchase Period
May 1, 2009 – Dec. 31, 2019
Varies slightly by settlement.
Why Are There So Many Different Websites?
This is the number one question people have, and the answer is simple once you understand it: there are multiple websites because there are multiple separate legal programs all dealing with the same underlying problem — generic drug companies allegedly conspired to fix prices — but through different legal channels.State attorneys general filed their own lawsuits in one court. A separate group of consumer class-action lawyers filed a federal class action in a different court. And the pharmacies and wholesalers who bought the drugs directly filed their own case. Each of those cases ends up with its own settlement, its own website, its own timeline, and its own claim form. There are three main programs. Here is what each one does and who it is for.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
Program 1: The End-Payer Site (GenericDrugsEndPayerSettlement.com) — Claims Open
Who it is for: "End-payers" — consumers who paid for drugs, and health insurers, employer plans, and union benefit plans that reimbursed drug costs.Who runs it: Class action attorneys in the federal MDL (In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-MD-2724, E.D. Pa.).
Claim form available? Yes — claims are now being accepted, with a deadline of November 9, 2026.
This is the federal class action program, and it is the one with an open claim window right now. Class counsel combined three now-final settlements into a single claims process: the Sandoz/Fougera settlement ($275 million, final approval September 26, 2025), the Sun/Taro settlement ($200 million, final approval January 23, 2026), and the Apotex and Heritage End-Payer settlements ($58 million combined, final approval in late 2025). The word "End-Payer" means anyone who ultimately paid for a covered drug — either you personally, or an insurance company or employer plan that paid on your behalf.
Program 2: The AG Consumer Site (AGGenericDrugs.com) — Register Only
Who it is for: Individual consumers — regular people who personally bought generic prescription drugs.Who runs it: A coalition of 48+ State Attorneys General, led by Connecticut.
Claim form available? Not yet — registration only.
This program is run by state attorneys general from nearly every state. It has now settled with five companies: Apotex ($39.1 million), Heritage ($10 million), Bausch ($4.08 million), Lannett ($13.77 million), and — newly, on July 15, 2026 — Glenmark Pharmaceuticals ($29.6 million), for a combined total of more than $96 million in the AG track. The Bausch and Lannett settlements received final approval on May 27, 2026. The AG program has not yet opened a consumer claim form; it appears to be waiting to accumulate money from multiple settlements before opening claims, and registrants will be notified by email when that happens. You can check whether your medications are covered on the program's official drug list.
Program 3: The Direct Purchaser Site (GenericDrugsDirectPurchaserSettlement.com)
Who it is for: Direct purchasers — pharmacies, wholesalers, and distributors that bought drugs directly from the manufacturers.Claim form available? Not applicable for most consumers.
This site is not for regular consumers. It is for businesses that bought generic drugs directly from manufacturers rather than from a pharmacy or retailer. If you are a regular person who bought prescriptions at a pharmacy, this site will redirect you to the End-Payer program.
Quick Comparison: Which Site Is for You?
| Website | Who It Is For | Run By | Claim Form Open? |
|---|---|---|---|
| Generic Drugs End-Payer Settlement | Consumers AND insurers / employer health plans | Federal class action attorneys (MDL, E.D. Pa.) | Yes — deadline Nov 9, 2026 |
| AG Generic Drugs | Individual consumers who bought generic Rx drugs | 48+ State Attorneys General | No — register for updates |
| Generic Drugs Direct Purchaser Settlement | Pharmacies, wholesalers, distributors only | Direct purchaser class attorneys | Not for consumers |
What Is This Case About?
Dozens of generic drug manufacturers are accused of conspiring to fix the prices of hundreds of commonly used prescription medications between 2009 and 2019. Instead of competing against each other to offer the lowest price — which is how generic drugs are supposed to work — these companies allegedly coordinated to keep prices artificially high, allocate market share, and avoid undercutting each other. The complaints allege the result was that millions of Americans and their health insurance plans paid more than they should have for everyday medications such as antibiotics, blood pressure drugs, antidepressants, diabetes medications, and thyroid treatments.The litigation is massive. It involves more than 60 named corporate defendants, dozens of individual executives, and hundreds of generic drugs. State attorneys general filed separate complaints, and the federal class action was consolidated into a Multi-District Litigation (MDL) in the Eastern District of Pennsylvania. Settlements have been reached with some companies, while litigation continues against many others. The defendants deny the allegations. The first trial is expected in late 2026 in Hartford, Connecticut.
How Much Money Is in These Settlements?
The combined settlement total across all three programs is now more than $850 million. Here is the breakdown of the settlements reached so far:| Settlement | Program | Amount | Status |
|---|---|---|---|
| Sandoz / Fougera | End-Payer | $275,000,000 | Final approval (Sept 26, 2025) · claims open |
| Sun / Taro | End-Payer | $200,000,000 | Final approval (Jan 23, 2026) · claims open |
| Apotex / Heritage | End-Payer | $58,000,000 | Final approval (late 2025) · claims open |
| Apotex | AG Consumer | $39,100,000 | Approved (Nov 2024) · register |
| Glenmark | AG Consumer | $29,600,000 | Announced July 15, 2026 · register |
| Lannett | AG Consumer | $13,770,000 | Final approval (May 27, 2026) · register |
| Heritage | AG Consumer | $10,000,000 | Approved (Nov 2024) · register |
| Bausch | AG Consumer | $4,080,000 | Final approval (May 27, 2026) · register |
Many other defendants — including Teva, Actavis, Amneal, Lupin, Mallinckrodt, Viatris (formerly Mylan), and others — remain in active litigation and have not settled. The separate direct-purchaser program (for pharmacies and wholesalers) has its own settlements on top of the figures above, which is how the combined total across all three programs exceeds $850 million.
Who Qualifies?
You may be eligible if you purchased, paid for, or reimbursed the cost of certain generic prescription drugs in the United States between May 1, 2009 and December 31, 2019. This includes individual consumers who personally paid for prescriptions at a pharmacy (out of pocket, copay, or coinsurance), health insurance companies that reimbursed drug costs, and employer or union benefit plans that paid for prescription drug coverage.The specific drugs covered include hundreds of common generics — for example Albuterol (asthma), Amoxicillin (antibiotic), Amlodipine and Lisinopril (blood pressure), Digoxin (heart), Doxycycline (antibiotic), Glyburide and Glipizide (diabetes), Levothyroxine (thyroid), Metoprolol (blood pressure/heart), Pravastatin (cholesterol), Sertraline (antidepressant), and Warfarin (blood thinner). This is not a complete list — check the official drug list for the full inventory.
How to File an End-Payer Claim
The End-Payer program is the one you can act on right now. File online at GenericDrugsEndPayerSettlement.com or by mail, with a deadline of November 9, 2026.Gather your documentation before you file: pharmacy records, prescription receipts, insurance explanation-of-benefits (EOB) statements, or other records showing which generic drugs you purchased and when. Consumers and third-party payers each have their own claim path within the program. Separately, register on AGGenericDrugs.com so you are notified when the state attorneys general open their consumer claim form. Filing on one program does not automatically file you on the other.
February 2026: The Novartis / Sandoz Lawsuit
On February 2, 2026, a coalition of 42 states and territories filed a new lawsuit against Novartis AG and its subsidiaries Sandoz Group AG and Sandoz AG. The complaint alleges Novartis conspired with other generic manufacturers to fix prices, allocate markets, and rig bids for 31 additional generic drugs. The complaint also alleges Novartis fraudulently transferred and drained assets from Sandoz Inc. — a separate entity already named as a defendant — and spun off Sandoz to shield itself from liability. These are allegations; the case is still pending and the defendants have not been found liable.Important Dates
• End-Payer Claim Deadline (Sandoz / Sun-Taro / Apotex-Heritage): November 9, 2026• AG Consumer Claim Form (Apotex / Heritage / Bausch / Lannett / Glenmark): Not yet open — register for updates
• First Trial (remaining defendants): Expected late 2026, Hartford, Connecticut
Dates can change by court order. Confirm the current schedule on the official settlement websites before you rely on any deadline.
Case Information
• Federal MDL: In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-MD-2724 (E.D. Pa.)• AG Cases: Complaints filed by 48+ state attorneys general in the U.S. District Court for the District of Connecticut
• Combined Settlement Total: More than $850 million across all three programs
• Class Period: May 1, 2009 to December 31, 2019 (varies by settlement)
• End-Payer Class Counsel: Fine, Kaplan and Black, R.P.C.
Sources and Resources
- End-Payer Program (claims open) — Generic Drugs End-Payer Settlement
- State AG Consumer Program (register) — AG Generic Drugs
- Connecticut Attorney General — Glenmark and Bausch/Lannett settlement announcements
- End-Payer Class Counsel — Fine, Kaplan and Black, R.P.C. (claim-forms notice)
For more class actions keep scrolling below.
Combined Settlements
Over $850 million (all three programs)
Case Title
In re Generic Pharmaceuticals Pricing Antitrust Litigation
Case Number
No. 16-MD-2724
Court
U.S. District Court, Eastern District of Pennsylvania (End-Payer MDL)
End-Payer Claim Deadline
November 9, 2026
End-Payer Class Counsel
Fine, Kaplan and Black, R.P.C.
Official Website
Generic Drugs End-Payer Settlement.com
